Trials / Completed
CompletedNCT03805581
Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
A Phase II Study to Determine the Safety of Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- New York Medical College · Academic / Other
- Sex
- All
- Age
- 2 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety of defibrotide in subjects with sickle cell disease (SCD)-associated acute chest syndrome (ACS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Defibrotide | Defibrotide 6.25 mg/kg IV q6h up to 7 days |
Timeline
- Start date
- 2018-01-12
- Primary completion
- 2022-07-01
- Completion
- 2023-11-07
- First posted
- 2019-01-15
- Last updated
- 2023-12-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03805581. Inclusion in this directory is not an endorsement.